ClinVar Miner

Submissions for variant NM_001042492.3(NF1):c.2851-6_2851-3del

dbSNP: rs1597716256
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 6
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Invitae RCV000802183 SCV000942001 pathogenic Neurofibromatosis, type 1 2023-10-24 criteria provided, single submitter clinical testing This sequence change falls in intron 21 of the NF1 gene. It does not directly change the encoded amino acid sequence of the NF1 protein. It affects a nucleotide within the consensus splice site. This variant is not present in population databases (gnomAD no frequency). This variant has been observed in individual(s) with clinical features of neurofibromatosis type 1 (PMID: 10862084, 27838393; Invitae). In at least one individual the variant was observed to be de novo. This variant is also known as IVS16-6del4. ClinVar contains an entry for this variant (Variation ID: 647632). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. For these reasons, this variant has been classified as Pathogenic.
Medical Genomics Laboratory, Department of Genetics UAB RCV000802183 SCV001167406 pathogenic Neurofibromatosis, type 1 2020-01-20 criteria provided, single submitter clinical testing
Institute of Human Genetics, Medical University Innsbruck RCV000802183 SCV001250658 pathogenic Neurofibromatosis, type 1 2020-01-20 criteria provided, single submitter clinical testing
Genome-Nilou Lab RCV000802183 SCV002561809 pathogenic Neurofibromatosis, type 1 2022-03-15 criteria provided, single submitter clinical testing
Ambry Genetics RCV002440682 SCV002752734 pathogenic Hereditary cancer-predisposing syndrome; Cardiovascular phenotype 2022-11-10 criteria provided, single submitter clinical testing The c.2851-6_2851-3delCTTT intronic pathogenic mutation, located in intron 21 of the NF1 gene, results from a deletion of 4 nucleotides within intron 21 of the NF1 gene. The variant has been detected in multiple individuals with neurofibromatosis type 1 (Messiaen LM et al. Hum Mutat, 2000;15:541-55; Calì F et al. Eur J Med Genet, 2017 Feb;60:93-99). RNA studies have demonstrated that this alteration results in skipping of exon 22 (Messiaen LM et al. Hum Mutat, 2000;15:541-55; Wimmer K et al. Hum Mutat, 2020 06;41:1145-1156; Ambry internal data). This variant is considered to be rare based on population cohorts in the Genome Aggregation Database (gnomAD). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation.
Fulgent Genetics, Fulgent Genetics RCV002501077 SCV002813204 pathogenic Neurofibromatosis, familial spinal; Juvenile myelomonocytic leukemia; Neurofibromatosis, type 1; Neurofibromatosis-Noonan syndrome; Café-au-lait macules with pulmonary stenosis 2021-09-16 criteria provided, single submitter clinical testing

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.